in vivo News and Research

RSS

InVivo Therapeutics to sponsor Working 2 Walk symposium

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the Company is the Title Sponsor of the 8th annual Working 2 Walk Science & Advocacy Symposium taking place September 27-28, 2013 at the Boston Convention & Exhibit Center in Boston, MA.

16 May 2013

Study finds novel delivery method that helps dissolve stroke-causing clots

A new study from the University of Cincinnati has found that, when delivered via ultrasound, the natural enzyme plasmin is more effective at dissolving stroke-causing clots than the standard of care, recombinant tissue plasminogen activator (rt-PA).

16 May 2013

Avian-origin influenza A virus associated with severe lower respiratory tract diseases

A novel avian-origin reassortant influenza A (H7N9) virus emerged in China in February 2013, and is associated with severe lower respiratory tract diseases. To date, more than 100 human cases of infection, including at least 20 deaths, have been reported in China.

15 May 2013

New technique can lead to effective use of nanoparticles as drug delivery system

A Wayne State University researcher has successfully tested a technique that can lead to more effective use of nanoparticles as a drug delivery system.

8 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Study: Surgeons training in robotic surgery learned best when three different teaching methods are used

By developing a new way to compare techniques for teaching robotic surgery, doctors at The Methodist Hospital and the University of Southern California report in an upcoming issue of the British Journal of Urology International that surgeons training in robotic surgery learned best when three different teaching methods were used.

6 May 2013

Pharmapendium adds new module to benefit researchers and toxicologists

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announces that PharmaPendium, the leading source of preclinical, clinical and post-market data, has added a new module to its content base, the Metabolizing Enzymes and Transporters Module.

6 May 2013

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Emergent BioSolutions Inc. today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) molecule, ES414, at the 9th Annual Protein and Antibody Engineering Summit, currently underway in Boston, MA.

3 May 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.

29 Apr 2013

Study demonstrates accuracy of non-invasive test for NASH diagnosis

A Chinese study presented at the International Liver CongressTM 2013 has demonstrated the accuracy of a non-invasive test for non-alcoholic steatohepatitis (NASH) diagnosis.

26 Apr 2013

New device allows automatic suturing of large intestine during cancer colon surgery

The Spanish research centre Innotex has developed a device that enables automatic suturing of the large intestine after being sectioned during cancer colon surgery. The novelty of the system, called Insewing, is that it allows the use of absorbable suture material instead of metallic staples which are currently used and could cause intestinal stiffness and obstruction.

26 Apr 2013

New hope for patients with chronic HBV infection

Exciting new data presented today at the International Liver Congress- 2013 include rults from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for chronic hepatitis B virus (HBV) infection.

25 Apr 2013

CNIO researcher-led consortium to receive MRA grant to advance research in melanoma

A consortium led by the Spanish National Cancer Research Centre's researcher Mar-a S. Soengas −Programme Director of the Centre-s Molecular Pathology Programme and Leader of the CNIO Melanoma Group− has been selected to receive funding from the Melanoma Research Alliance, the most important private international melanoma research foundation, in order to advance research in melanoma; this type of skin tumour represents one of oncology's biggest challenges due to its high incidence and malignancy.

24 Apr 2013

Investigators report that cell-permeable NLS peptide shows promise in controlling atherosclerotic disease

Atherosclerosis - sometimes called "hardening of the arteries" - is a leading cause of death and morbidity in Western countries. A cell-permeable peptide containing the NF-ĸB nuclear localization sequence (NLS) shows promise as a potential agent in controlling the development of atherosclerotic disease.

18 Apr 2013

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.

12 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

Spencer Trask applauds InVivo for getting FDA approval to test biopolymer scaffold in humans

Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.

6 Apr 2013

FDA approves InVivo Therapeutics' IDE to test biopolymer scaffold product in humans

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the U.S. Food and Drug Administration has approved the Company's Investigational Device Exemption to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI.

5 Apr 2013

in vivo News and Research

InVivo Therapeutics to sponsor Working 2 Walk symposium

Study finds novel delivery method that helps dissolve stroke-causing clots

Avian-origin influenza A virus associated with severe lower respiratory tract diseases

New technique can lead to effective use of nanoparticles as drug delivery system

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Study: Surgeons training in robotic surgery learned best when three different teaching methods are used

Pharmapendium adds new module to benefit researchers and toxicologists

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Study demonstrates accuracy of non-invasive test for NASH diagnosis

New device allows automatic suturing of large intestine during cancer colon surgery

New hope for patients with chronic HBV infection

CNIO researcher-led consortium to receive MRA grant to advance research in melanoma

Investigators report that cell-permeable NLS peptide shows promise in controlling atherosclerotic disease

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spencer Trask applauds InVivo for getting FDA approval to test biopolymer scaffold in humans

FDA approves InVivo Therapeutics' IDE to test biopolymer scaffold product in humans

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News